Saturday, January 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Operation Warp Speed’s Big Vaccine Contracts Could Stay Secret

by Global Biodefense Staff
September 29, 2020
The Role of the Science Advisory Group for Emergencies (SAGE) in Pandemic Response

Credit: Global Biodefense

Instead of entering into contracts directly with vaccine makers, more than $6 billion in Operation Warp Speed funding has been routed through a defense contract management firm called Advanced Technologies International, Inc. ATI then awarded contracts to companies working on COVID-19 vaccines.

As a result, the contracts between the pharmaceutical companies and ATI may not be available through public records requests, and additional documents are exempt from public disclosure for five years.

Vaccine contracts awarded this way include $1.6 billion for Novavax, $1.95 billion for Pfizer, $1.79 billion for Sanofi and $1 billion for Johnson & Johnson.

NPR first began looking into the possibility of a third party when HHS responded that it had “no records” in response to a federal Freedom of Information Act request for the $1.6 billion vaccine contract with Novavax, which the agency announced in July.

Read more by Sydney Lupkin at NPR

Trump administration’s project to develop a Covid-19 vaccine – which is funneling money through a nongovernmental intermediary, a move that is likely to reignite worries over the project’s opaque nature.

Operation Warp Speed’s opaque choices of COVID-19 vaccines draw Senate scrutiny

At Senate subcommittee hearing on 2 July 2020 that focused on Warp Speed, scientists at the front of the effort, after repeated questioning, gave limited answers about the vaccine candidates they have chosen for funding and their selection criteria.

At the opening of the hearing—held by the Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies—Senator Patty Murray (D–WA) put the witnesses on notice that she wanted straightforward answers on many issues. “We’re going to need to hold this administration accountable to avoid repeating mistakes and delays,” Murray said. “The administration still has not provided any explanation of how it is selecting vaccine candidates, what the risks are of narrowing down that shortlist or addressed concerns about potential conflicts in contracts that predate this crisis.”

Read more by Jon Cohen at Science

Tags: COVID CountermeasuresCOVID-19Editor PickSARS-CoV-2Vaccines

Related Posts

Biodefense Headlines – 24 January 2023
News Scan

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023
News Scan

Biodefense Headlines – 17 January 2023

January 17, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC